Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced a new scientific poster on recombinant human albumin to be presented at the 2011 AAPS National Biotechnology Conference, May 16-18, San Francisco, California. The poster reveals the results of the company's latest study on the use of recombinant human albumin for the stabilization of therapeutic proteins. For more information or to request a copy of the scientific poster, please visit table #32 at the 2011 AAPS National Biotechnology Conference.
The therapeutic and ultimately the commercial success of a protein-based drug depends upon the ability to produce a formulation with an adequate stability profile. The mechanisms of protein instability are complex and typically multiple excipients are required to address factors such as aggregation, oxidation and nonspecific adsorption during protein formulation.
"We are proud to present our latest, breakthrough research on recombinant human albumin and share our invaluable knowledge with other industry experts", comments Dermot Pearson, marketing director at Novozymes Biopharma. "As a leader in biomanufacturing and process development, we continue to perform studies designed to demonstrate how animal-free rAlbumin can help the industry optimize drug formulation, development and delivery."
The new poster, entitled "Recombinant Human Albumin: A Multifunctional Excipient for the Stabilisation of Therapeutic Protein Formulations", demonstrates the potential for recombinant human albumin (rAlbumin) to act as a multifunctional stabilisation excipient for protein and peptide formulations. The poster describes the study undertaken to investigate the stability of the rAlbumin with respect to pH and temperature to assess the suitability of this molecule for incorporation into protein formulations.
The study results indicate that rAlbumin is a multifunctional excipient, protecting protein-based active ingredients against aggregation, oxidation and non-specific binding in solution. The multifunctional nature of rAlbumin may lead to opportunities to explore simpler protein formulations with reduced numbers of excipients. Additionally, the stability of the molecule reveals its potential to be used under a wide range of formulation conditions.
For further information on Novozymes products or to request a copy of the new scientific poster, please visit table #32 at the 2011 AAPS National Biotechnology Conference.
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.
Sally Vernon, Customer Communications Manager SYKE[.]novozymes.com T: +44 115 955 3355
Europe - René Tronborg
Office: +45 4446 2274 / Mobile: +45 3077 2274 - retr[.]novozymes.com.
US - Paige Donnelly
Office: +1 919 494 3209 / Mobile: +1 919 218 4501 - pagd[.]novozymes.com.
China - Zhu Xiaoqing
Office: +86 106 298 7888+362 / Mobile: +86 138 012 40590 - xqzh[.]novozymes.com.
Brazil - Saionara Ribeiro de Paula
Office: +55 41 3641 1112 / Mobile: +55 41 9971 7225 - saio[.]novozymes.com.
Europe - Tobias Bjorklund
Office: +45 4446 8682 / Mobile: +45 3077 8682 - tobb[.]novozymes.com.
US - Thomas Steenbech Bomhoff
Mobile: +1 919 649 2565 / tsbm[.]novozymes.com.